Pos­i­tive piv­otal da­ta in hand, GBT is hus­tling to the FDA in search of a quick OK for sick­le cell drug -- but that's no easy task

Glob­al Blood Ther­a­peu­tics sur­prised some ob­servers this morn­ing with their plan to take the first round of pos­i­tive late-stage da­ta for the sick­le cell dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER